<DOC>
	<DOCNO>NCT00250718</DOCNO>
	<brief_summary>1.1 To determine efficacy combination treatment VP-16 , chlorambucil , dexamethasone , vincristine patient relapsed/refractory hematological malignancy . 1.2 To determine toxicity profile regimen patient population . 1.3 Evaluate effect low dose administration chemotherapy angiogenesis , correlate tumor response .</brief_summary>
	<brief_title>Study : Treatment Relapsed Lymphoid Malignancies With Anti-Angiogenic Approach</brief_title>
	<detailed_description>The purpose study see effective combination chemotherapy drug VP-16 , chlorambucil , dexamethasone , vincristine patient blood cancer return respond prior treatment . Some patient may also receive medication call rituximab doctor think appropriate . This drug combination give study participant low dose continuous basis . The study also collect information side effect drug combination patient type cancer . Previous study patient non-Hodgkin 's lymphoma indicate patient treat drug combination achieve high response . The aim study test drug combination control setting .</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>All patient , 18 year age old , Hodgkin 's lymphoma , NonHodgkin lymphoma ( NHL ) , multiple myeloma ( MM ) , chronic lymphocytic leukemia ( CLL ) eligible . Patients must life expectancy least 12 week . Patients must Zubrod performance status 02 . Patients must sign informed consent . Patients adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,000 cells/mm3 platelet count &gt; 50,000/mm3 absence regular red blood cell platelet transfusion requirement . Patients adequate hepatic function total bilirubin &lt; 2 mg/dl SGOT SGPT &lt; two time upper limit normal , adequate renal function define serum creatinine &lt; 2.0 x upper limit normal . Patients must receive least two previous chemotherapy regimens disease . Patients must measurable disease ( NHL ) evaluable disease ( MM , CLL ) . Patients symptomatic brain metastasis exclude study . Pregnant woman nurse mother eligible trial . Patients child bear potential must use adequate contraception . Patients may receive concurrent chemotherapy radiation therapy trial . Patients severe medical problem uncontrolled diabetes mellitus cardiovascular disease active infection eligible trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Non Hodgkin 's Lymphoma</keyword>
	<keyword>Phase II</keyword>
	<keyword>Lymphoid malignancy</keyword>
</DOC>